menu
    • menu
    [{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Olutasidenib","moa":"||IDH-1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Optime Care","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optime Care \/ Optime Care","highestDevelopmentStatusID":"15","companyTruncated":"Optime Care \/ Optime Care"},{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Pralsetinib","moa":"||RET receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Optime Care","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Optime Care \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Optime Care \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"Optime Care","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"||SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Optime Care","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optime Care \/ Optime Care","highestDevelopmentStatusID":"15","companyTruncated":"Optime Care \/ Optime Care"}]

    Find Clinical Drug Pipeline Developments & Deals by Optime Care

    Menu

    Optime Care

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Optime Care Expands TAVALISSE® Distribution with Rigel Pharmaceuticals

                            Details : Under the agreement, Optime Care will commercialize three Rigel products, which includes Tavalisse (fostamatinib disodium hexahydrate), indicated for the treatment of thrombocytopenia.

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 16, 2024

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pralsetinib,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Optime Care Announces Enhanced Partnership with Rigel for GAVRETO® Patients

                            Details : The partnership aims to assist in the commercialization of Rigel Pharmaceuticals' approved product, Gavreto (pralsetinib), which is indicated for RET fusion-positive non-small cell lung cancer.

                            Product Name : Gavreto

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 27, 2024

                            Lead Product(s) : Pralsetinib,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Optime Care

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olutasidenib,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Phar...

                            Details : Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

                            Product Name : Rezlidhia

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 13, 2022

                            Lead Product(s) : Olutasidenib,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Rigel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth